Back to top
more

Elanco Animal Health (ELAN)

(Delayed Data from NYSE)

$14.20 USD

14.20
6,771,341

+0.13 (0.92%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.22 +0.02 (0.14%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.

Kinjel Shah headshot

Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.

Zacks Equity Research

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

by Zacks Equity Research

Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.

Zacks Equity Research

Elanco Animal Health (ELAN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 25% and 3.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RadNet (RDNT) Q2 Earnings Match Estimates

by Zacks Equity Research

RadNet (RDNT) delivered earnings and revenue surprises of 0% and 5.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elanco Animal Health (ELAN) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Elanco Animal Health (ELAN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Option Care (OPCH) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 7.14% and 4.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Kinjel Shah headshot

Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.

Zacks Equity Research

Elanco (ELAN) Stock Declines After Sale of Aqua Business

by Zacks Equity Research

Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Kinjel Shah headshot

Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?

by Kinjel Shah

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

Zacks Equity Research

Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers

by Zacks Equity Research

Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.

Zacks Equity Research

Elanco Animal Health (ELAN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Elanco Animal Health (ELAN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

U.S. Physical Therapy (USPH) Misses Q1 Earnings Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -12.07% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Elanco Animal Health (ELAN) Q1 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Elanco Animal Health (ELAN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks Equity Research

Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q4 Earnings

by Zacks Equity Research

The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Analysts Estimate U.S. Physical Therapy (USPH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Get a deeper insight into the potential performance of Elanco Animal Health Incorporated (ELAN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH